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ABSTRACT 
Parkinson’s Disease (PD) is an idiopathic disorder with no known cure. With 
number of cases steadily rising around the world, it is imperative to turn to the underlying 
cellular and molecular mechanisms of the disease manifestation and neurodegeneration to 
craft novel modes of therapy. VPS35 is one of the few genes that have identified and 
definitively linked to familial PD. The particular mutation that has been associated is 
known to cause dysfunction of a key cellular process known as autophagy. This process 
is primarily responsible for clearance of unwanted, damaged or misfolded proteins, 
among other things. Our study reveals an important link between VPS35, PI3K-AKT 
signaling pathway and autophagy dysfunction that might be a potential mechanism of PD 
pathogenesis. We also address possible perturbed dopaminergic neurogenesis in the 
substantia nigra brain region as a second plausible disease mechanism, as well as a target 
for therapeutic intervention. 
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CHAPTER ONE: A REVIEW OF THE CONTRIBUTIONS OF VPS35 MUTATIONS 
IN PARKINSON’S DISEASE 
Parkinson’s Disease (PD) is a multi-system neurodegenerative disease where 
approximately 90% of cases are idiopathic. The remaining 10% of the cases can be traced 
to a genetic origin and research has largely focused on these associated genes to gain a 
better understanding of the molecular and cellular pathogenesis for PD. The gene 
encoding vacuolar protein sorting protein 35 (VPS35) has been definitively linked to late 
onset familial PD following the identification of a point mutation (D620N) as the causal 
agent in a Swiss family. Since its discovery, numerous studies have been undertaken to 
characterize the role of VPS35 in cellular processes and efforts have been directed toward 
understanding the perturbations caused by the D620N mutation. In this chapter, we 
examine what is currently known about VPS35, which has pleiotropic effects, as well as 
proposed mechanisms of pathogenesis by the D620N mutation. A brief survey of other 
VPS35 polymorphisms is also provided. Lastly, model systems that are being utilized for 
these investigations and possible directions for future research are discussed. 
Introduction 
Parkinson’s disease (PD) is a complex neurological disorder involving both motor 
and non-motor symptoms. Affecting 1% of the population over 60, it is the second most 
common neurodegenerative disorder (Lau & Breteler, 2006; Williams-Gray et al., 2013). 
The prevalence of the disease rises with age. According to a meta-analysis report by 
Pringsheim, Jette, Frolkis, & Steeves, (2014), the prevalence is 41 per 100000 between 
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ages 40 and 49, rising up to 428 between ages 60 and 69 and 1087 between 70 and 79. 
Another report states that there is a greater incidence in men compared to women, at a 
ratio of approximately 1.5:1 (Elbaz et al., 2002; K. S. M. Taylor, Cook, & Counsell, 
2007; Wooten, Currie, Bovbjerg, Lee, & Patrie, 2004). The case burden in the US alone 
is estimated to rise to more than one million by 2030 (Marras et al., 2018).The loss of 
motor function occurs primarily due to a loss of dopamine signaling in the basal ganglia. 
This loss of dopamine is, in turn, due to the progressive loss of dopaminergic neurons in a 
region of the brain known as the substantia nigra. However, it is not only the basal 
ganglia that is affected in PD. Research suggests that it involves multiple areas of the 
brain and results from a complex interplay between genetic and environmental factors. 
Clinically described motor symptoms include resting tremors, bradykinesia, rigidity of 
limbs and gait defects. Moreover, there are numerous non-motor symptoms such as 
cognitive defects and dementia, mood disorders and sleep disorders that add to the 
suffering of the patients (Ascherio & Schwarzschild, 2016; Pringsheim et al., 2014; 
Tysnes & Storstein, 2017). According to the centers for disease control and prevention 
(CDC), medical complications due to PD rank as the 14th leading cause of death in the 
United States (Beard et al., 2017). With no known cure for this disease, research has been 
focused on understanding the cellular and molecular processes that may be responsible 
for the neurodegeneration.  
In terms of neuropathology, some of the hallmarks of PD are the loss of dopamine 
producing neurons in the substantia nigra and the formation of toxic protein aggregates in 
surviving neurons. Neurofibrillary tangles composed of α-synuclein aggregates formed 
structures called Lewy bodies in these neurons. This is also accompanied by 
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mitochondrial dysfunction (Goswami, Joshi, & Singh, 2017). The pathology of the α-
synuclein aggregates resembles features of prion disease. This has led to the hypothesis 
that α-synuclein has prion properties (Brundin & Melki, 2017; Surmeier, Obeso, & 
Halliday, 2017). Some of the genes associated with PD that have been described include 
SNCA, LRRK2, VPS35, CHCHD2, GBA, Parkin, PINK1, DJ-1, ATP13A2, FBXO7 and 
PLA2G6. These genes have also been reported to disrupt mitochondrial function and 
biogenesis (Helley, Pinnell, Sportelli, & Tieu, 2017). Protein homeostasis, particularly 
synucleinopathy, and mitochondrial health have therefore become major areas of focus 
for research into characterizing PD pathogenesis and developing therapeutics. 
Identified VPS35 Mutations 
The VPS35 gene was identified by two independent studies in 2011 as linked to 
familial PD (Vilariño-Güell et al., 2011; Zimprich et al., 2011). These studies were 
conducted using exome sequencing technology on DNA obtained from families that 
exhibited evidence of hereditary PD. Subsequent studies have largely concluded that the 
D620N mutation is relatively rare, with a calculated prevalence of about 0.115%, from 15 
reported case studies involving 21824 PD patients worldwide (Ando et al., 2012; 
Blanckenberg, Ntsapi, Carr, & Bardien, 2014; Chen et al., 2013; H Deng et al., 2012; 
Hao Deng, Gao, & Jankovic, 2013; Gagliardi, Annesi, Tarantino, Nicoletti, & Quattrone, 
2014; Gambardella et al., 2016; Guella et al., 2012; Guo et al., 2012; Gustavsson et al., 
2015; Koschmidder, Mollenhauer, Kasten, Klein, & Lohmann, 2014; Kumar et al., 2012; 
Lesage et al., 2012; Shannon et al., 2014; Sharma et al., 2012; Sheerin et al., 2012; 
Sudhaman et al., 2013; Y. Zhang et al., 2012). Other polymorphisms in the VPS35 gene 
that were identified include L774M, P316S, R524W, I241M, M57I, G51S, R32S, I560T, 
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H599R, M607V. However, all of these sequence variations, with the exception of 
D620N, have yet to be definitively linked to PD.  
In 2005, a study identified VPS35 levels to be reduced in affected brain regions in 
Alzheimer’s disease (Small et al., 2005). Another study then reported increased Amyloid 
β depositions in mice heterozygous for VPS35 knockout (Vps35+/m) (Wen et al., 2011). 
Similarly, other studies have linked abnormal microglial activity and abnormal 
hippocampal development, as observed in Alzheimer’s Disease, to VPS35 depletion, but 
no polymorphisms in the VPS35 gene have been associated(Appel et al., 2018; C.-L. 
Wang et al., 2012). 
VPS35 as Part of the Retromer Complex and Related Functions  
VPS35 was originally identified in yeast as part of a protein complex called the 
retromer complex. This complex is involved in cellular trafficking (M. N. Seaman, 
McCaffery, & Emr, 1998). Especially, its role in endosome to Golgi retrograde transport 
has been very well characterized (Follett et al., 2014b; Matthew N J Seaman, 2012; 
Trousdale & Kim, 2015). Since its identification, retromer dysfunction has been 
implicated in Alzheimer’s disease, Parkinson’s disease and several other 
neurodegenerative diseases, along with various developmental processes, including wing 
and eye development in Drosophila, and bone development (Belenkaya et al., 2008; 
Chan et al., 2016; P. Zhang, Wu, Belenkaya, & Lin, 2011). In this context, the interaction 
of the retromer complex and the Wnt signaling pathway has been extensively studied 
(Belenkaya et al., 2008; Chan et al., 2016; Small & Petsko, 2015; S. Wang & Bellen, 
2015; P. Zhang et al., 2011; Q. Zhang et al., 2018). Structurally, VPS35 forms a trimer 
with VPS26 and VPS29, to form what is known as the cargo recognition complex (CRC). 
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This CRC then associates with a dimer of sorting nexins, belonging to the SNX-BAR 
family of proteins. This association is further facilitated by RAB7. Together, the retromer 
complex plays important roles in vesicular sorting (Bonifacino & Hurley, 2008; Lucas et 
al., 2016; McGough & Cullen, 2011; M. N. J. Seaman, Harbour, Tattersall, Read, & 
Bright, 2009; Matthew N J Seaman, 2012). Deficiency of either VPS35 or VPS29 leads 
to the degradation of the other two CRC components (Fuse et al., 2015). Transmembrane 
receptors such as the cation independent mannose 6 phosphate receptor (CIMPR) and the 
membrane iron transporter DMT1 are well characterized targets of retromer mediated 
sorting (Arighi, Hartnell, Aguilar, Haft, & Bonifacino, 2004; Lucas et al., 2016; Tabuchi, 
Yanatori, Kawai, & Kishi, 2010). In addition, there have been several studies on the role 
of the retromer in recycling of beta-2 adrenergic receptors (β2AR) in dendritic cells and 
trafficking of G protein coupled receptors (GPCRs) (Bahouth & Nooh, 2017; Bowman, 
Shiwarski, & Puthenveedu, 2016; Bunnett & Cottrell, 2010; Choy et al., 2014; Feinstein 
et al., 2011; McGarvey et al., 2016; Pavlos & Friedman, 2017; Sposini et al., 2017). The 
retromer is known to carry cargo from endosomes to the trans-Golgi network (TGN), 
performing retrograde transport, as well as carrying cargo from endosomes to the plasma 
membrane, allowing recycling of membrane bound receptors (Trousdale & Kim, 2015). 
Moreover, included in the list of retromer cargo, are degradative enzymes such as 
Cathepsin D, which are important for lysosomal function and could potentially influence 
autophagy. Furthermore, amyloid precursor protein (APP) and α-synuclein (SNCA) are 
also reported to be sorted by the retromer complex (Aufschnaiter, Kohler, & Büttner, 
2017; Follett et al., 2014b; Follett, Bugarcic, Collins, & Teasdale, 2017; Gallon & Cullen, 
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2015; C. Li, Shah, Zhao, & Yang, 2016; Miura et al., 2014; Reitz, 2018). These findings 
have sparked considerable interest in the contributions of the retromer to human diseases. 
Proposed Mechanisms of VPS35 in Neuronal Dysfunction 
The importance of the roles played by the retromer complex in signal transduction 
and receptor trafficking points to the dysfunction of the retromer as the major potential 
mechanism of neuronal degeneration caused by the VPS35 D620N mutation (Follett et 
al., 2014b, 2017; Reitz, 2018; Small & Petsko, 2015; S. Wang & Bellen, 2015). Out of 
the three components of the core retromer complex, VPS35-VPS26-VPS29, knockdown 
of any one component, except VPS26, leads to the degradation of the other two 
components (Fuse et al., 2015). Therefore, given that any free VPS35, existing outside 
the retromer complex, is rapidly degraded, the role of VPS35 D620N in PD is likely to 
involve altered retromer function. Trafficking defects of AMPA receptors was reported in 
a VPS35 heterozygote mouse model as well as cultured mouse hippocampal and cortical 
dopaminergic neurons treated with VPS35 shRNA (Munsie et al., 2015; Tian et al., 
2015). Additionally, dopamine receptor D1 (DRD1) is also reported to be recycled with 
the involvement of VPS35 (C. Wang et al., 2016). 
Studies have reported reduced ⍺-synuclein degradation in VPS35 deficient cells 
(Braschi et al., 2010; Miura et al., 2014; Sugiura, McLelland, Fon, & McBride, 2014; F.-
L. Tang et al., 2015). Formation of toxic ⍺-synuclein aggregates and fibril formation are 
hallmarks of PD (Patel & Witt, 2018). This accumulation has been attributed to abnormal 
sorting of degradative enzymes that are normally targeted to the lysosome. However, this 
accumulation could also be partially due to autophagy defects, which have also been 
reported in HeLa cells expressing the VPS35 D620N mutation, attributed to impaired 
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WASH (Wiskott–Aldrich syndrome protein and SCAR homolog) complex association 
(McGough et al., 2014; Zavodszky et al., 2014). Given that autophagy is a major process 
responsible for removing proteins, macromolecules and organelles, this is another 
potential mechanism for the neurodegeneration caused by VPS35 (Barth, Glick, & 
Macleod, 2010; Lynch-Day, Mao, Wang, Zhao, & Klionsky, 2012; Tofaris, 2012) 
 
Figure 1.1 Cellular processes affected by VPS35 mutations 
Furthermore, defects in mitochondrial fusion and function have also been reported 
in some studies (Fu-Lei Tang et al., 2015; W. Wang et al., 2016). Mitochondrial 
dysfunction has been shown to affect neuronal function severely and is believed to be a 
driving force of neurodegeneration (Haelterman et al., 2014; Hauser & Hastings, 2013; 
Mullin & Schapira, 2013; Subramaniam & Chesselet, 2013; Winklhofer, 2014). Also, it 
is noteworthy that autophagy is the means by which damaged mitochondria are turned 
over (Ashrafi & Schwarz, 2013). Therefore, disruption in autophagy due to VPS35 
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D620N mutation may also result in, if not exacerbate, any mitochondrial dysfunction that 
may be directed by the VPS35 D620N mutation. 
Current Model Organisms and Systems for Studying VPS35 
Cell Culture 
A variety of tissue culture model systems are available for studying the structure 
and function of VPS35, and the pathogenic effects of its mutations. SH-SY5Y 
neuroblastoma cells can easily be induced to adopt a dopaminergic state by treatment 
with retinoic acid (Korecka et al., 2013; Krishna et al., 2014; Shipley, Mangold, & 
Szpara, 2016). This system was used by Tang et al (2015) to demonstrate mitochondrial 
impairment due to VPS35 deficiency as well as due to the D620N mutation (Fu-Lei Tang 
et al., 2015). This system was also used to characterize the role of VPS35 in lysosomal 
clearance of AIMP2, which is a substrate of the PD associated gene, Parkin (Yun et al., 
2017). Microglial BV2 cells have been used in some studies to understand the role of 
VPS35 in Alzheimer's Disease, and microglial physiology (Lucin et al., 2013; Yin et al., 
2016). In addition, HEK 293T cells also present a popular choice for understanding 
cellular pathways affected by VPS35 and retromer function due to their high plasmid 
transfection efficiency (Follett et al., 2014a; Williams et al., 2018; Yang et al., 2008). 
McGough et al (2014) used HeLa and RPE-1 cell lines to establish the interaction of 
VPS35 and FAM21 of the WASH complex (McGough et al., 2014). Cell lines can 
readily be transfected or virally transduced with an siRNA, shRNA or overexpression 
vectors to modulate the expression of VPS35 and other genes of interest (Nayerossadat, 
Maedeh, & Ali, 2012). Korolchuk et al. (2007) knocked down VPS35 in Drosophila S2 
cells using an RNAi approach, in order to identify novel proteins important for 
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endocytosis, where candidate proteins were selected based on binding predictions to 
either α adaptin or clathrin heavy chain, or on having a predicted membrane bending 
domain (such as the BAR domain). These candidate proteins were then knocked down to 
screen for subsequent endocytosis defects. VPS35 was among the short list of proteins 
that were identified as exhibiting a significant reduction in endocytosis, where the effect 
due to VPS35 was the most severe (Korolchuk et al., 2007). 
In addition to immortalized cell lines, primary neuronal and glial cultures have 
also been used to investigate VPS35 functions and mutations (F.-L. Tang et al., 2015; 
Tsika et al., 2014; Wen et al., 2011; Williams et al., 2018). Tang et al (2015) isolated and 
cultured dopaminergic neurons from brains of mice expressing microRNA directed 
against VPS35 (F.-L. Tang et al., 2015). These cells were found to have a reduced 
expression of MFN-2 or Mitofusin, and exhibited mitochondrial fragmentation, as well as 
impaired mitochondrial function. Similar results were obtained using SH-SY5Y and NLT 
neuroblastoma cultures (Fu-Lei Tang et al., 2015). In the study conducted by Tsika et al 
(2014), rat primary cortical cultures were used to show that overexpression of human 
VPS35 resulted in neuronal cell death and higher sensitivity to cellular stress like as 
reported in PD cases (Tsika et al., 2014). Wen et al (2011) demonstrated using mouse 
hippocampal slice cultures that VPS35 haploinsufficiency exacerbates long term 
potentiation impairment already present in mice expressing Swedish mutant form of the 
amyloid precursor protein (Wen et al., 2011). Williams et al (2018) discovered a novel 
link between the PD gene, Parkin, and VPS35, wherein Parkin mediates ubiquitination of 
VPS35, which does not affect VPS35 turnover, but may have a role to play in the 
retromer mediated endosomal sorting (Williams et al., 2018). Using primary cortical 
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neurons, they identified ATG9A, a WASH-dependent retromer cargo, to be missorted 
upon silencing of the Parkin gene. Using cell lines and primary cultures can therefore be 
very powerful tools for deciphering molecular mechanisms under precisely controlled 
conditions. 
Mice 
Homozygous knockout of VPS35 is embryonically lethal in mice. To overcome 
this challenge several mice models have been developed, including a hemizygous 
deletion mutant (Wen et al., 2011). This mutant was used to demonstrate that VPS35 
interacts with the protease BACE-1, predominantly responsible for Amyloid beta 
production, and that VPS35 reduction increases BACE-1 activity in the mouse 
hippocampus. In addition, A VPS35 D620N knock-in strain of mice has been developed 
recently by Cataldi et al (2018), in collaboration with Jackson Laboratories, to further 
characterize dopamine release and monoamine transporters in a VPS35 D620N mutant 
background (Cataldi et al., 2018). These mice were generated by Cre-recombinase 
mediated recombination of the VPS35 exon 15, on chromosome 8. These mice exhibited 
no detectable movement disorders and were similar in locomotion to non-transgenic 
mice. However, the dopamine turnover was reported to be increased. Dopamine 
transporter levels were reported to have been reduced while vesicular monoamine 
transporter levels were increased (Cataldi et al., 2018). Mir and colleagues (2018) used 
these same mice to study the interaction between LRRK2 and VPS35 (Mir et al., 2018). 
Using this model, they were able to demonstrate that the VPS35 D620N mutation 
increases LRRK2 catalyzed phosphorylation of three different RAB proteins, RAB 8a, 10 
and 12. They concluded that the VPS35 D620N mutation causes a gain of function with 
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respect to the kinase activity of LRRK2 and is an upstream regulator (Mir et al., 2018). A 
similar mouse model, generated using a CRISPR/Cas-9 mediated knock-in strategy, was 
used previously by Ishizu et al. (2016) to characterize reduced dopamine release in the 
striatum of heterozygous mice with one gene copy of VPS35 D620N knocked in 
(VPS35D620N KI), while the other copy had one base pair deleted in exon 15, creating a 
premature stop codon, referred to as VPS35Del1 (Ishizu et al., 2016). These 
VPS35D620NKI/VPS35Del1 heterozygous mice also displayed premature death and 
significant neurodegeneration throughout life, indicating that this model could be of 
considerable value for Parkinson’s Disease research. 
Rat 
A transgenic rat model generated via lentivirus mediated gene transfer has been 
described and utilized by Tsika et al., (2014). These rats overexpressed one of two human 
VPS35 constructs, one of wild type and the other containing the D620N mutation. 
However, the researchers concluded that the human D620N construct did not alter 
vesicular sorting of retromer cargo proteins in primary cortical neurons from these 
animals. They went on to confirm this finding in yeast and human (patient donated) 
fibroblasts. Contrary to this finding, the human VPS35 D620N overexpression was found 
to induce neurodegeneration in the substantia nigra of these rats suggesting that, in this 
model, VPS35 D620N might be primarily causing neuronal loss without altering retromer 
function (Tsika et al., 2014). 
Drosophila Melanogaster 
MacLeod et al (2013) used an overexpression vector to demonstrate that 
overexpression of wild type VPS35 reduced the defects caused by LRRK2 G2019S 
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mutation, and those caused by RAB7L1 knockdown. This was shown in LRRK2 mutant 
flies and primary rat neuronal cultures (MacLeod et al., 2013). Similarly, a VPS35 
overexpressing strain of flies was used by Linhart et al in 2014, to demonstrate the rescue 
of LRRK mutation derived eye defects, by eye specific VPS35 overexpression in 
Drosophila (Linhart et al., 2014), obtained from the Bloomington Drosophila Stock 
Center. In another study, flies with the Drosophila VPS35 (dVps35) knocked out, were 
shown to be embryonically lethal (Inoshita et al., 2017). This lethality could not be 
rescued by knock-in of human VPS35 wild type or human VPS35 D620N. However, it 
was rescued by knock-in of dVps35 WT and by knocking in dVps35 D647N (the 
Drosophila analog of the D620N mutation in humans). Using transgenic flies expressing 
wild type dVps35 or dVps35 D647N, in all three possible dVps35 heterozygote and 
homozygote backgrounds (+/+, +/-, -/-), they were then able to demonstrate that 
Drosophila LRRK (dLRRK) and dVps35 affect synaptic architecture and endocytosis via 
the same pathways (Inoshita et al., 2017). 
Saccharomyces Cerevisiae and Caenorhabditis Elegans 
Dhungel et al (2015) discovered that in VPS35 deficient yeast cells, EIF4G1 
upregulation was highly toxic, but the two mutations by themselves were not lethal 
(Dhungel et al., 2015). EIF4G1 is a translation initiation factor scaffold protein, 
responsible for the translation initiation complex formation (Villa, Do, Hershey, & 
Fraser, 2013). While they could not establish a direct interaction between the two 
proteins, a few common pathways were identified leading to the hypothesis that they 
were functionally related. The authors also noted that in a VPS35 null background, 
overexpression of EIF4G1 resulted in fewer but larger synaptic boutons. This group then 
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investigated proteotoxic stress in yeast cells and activation of the unfolded protein 
response (UPR). It was seen that there was increased proteotoxic stress and UPR 
activation in VPS35 deletion mutants, only upon overexpressing EIF4G1. This led to the 
conclusion that the EIF4G1 upregulation combined with retromer dysfunction was 
causing toxic protein aggregation. In addition, they demonstrated that Sortillin functions 
downstream of VPS35 or in parallel and is able to suppress the EIF4G1 overexpression 
toxicity in VPS35 deletion mutants. Lastly, this group showed, using yeast, C. elegans 
and transgenic mice that VPS35 deletion increases alpha synuclein driven toxicity. In 
transgenic mice, increased toxicity was also seen after overexpression of VPS35 D620N 
and VPS35 P316S (Dhungel et al., 2015). Therefore, altered VPS35 function can 
facilitate protein aggregation, a hallmark of PD. 
Future Research Directions  
With the advent of CRISPR/Cas-9 mediated genome editing technology, 
therapeutic applications targeting the VPS35 gene can now be conceived (Calatayud, 
Carola, Consiglio, & Raya, 2017). This could potentially be done in inducible pluripotent 
stem cells, obtained from patients, genetically modified and transplanted into the affected 
individuals’ brains. This technique has recently been described and is awaiting U.S Food 
and Drug Administration approval (Loring, 2018). A major obstacle in such an approach 
is the prion like properties of α-synuclein aggregates (Brundin & Melki, 2017). The pre-
existing toxic α-synuclein aggregates in the patient’s existing brain environment may 
induce the formation of α-synuclein fibrils in the transplanted cells, thus negating any 
corrections made in the genome. Similar outcome was observed in patients who received 
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embryonically derived grafting (Kordower, Chu, Hauser, Freeman, & Olanow, 2008; J.-
Y. Li et al., 2008). 
In addition, further characterization of the VPS35 D620N knock-in mice is now 
required to properly investigate the cellular pathways that are perturbed. With this in vivo 
model system, work done with in vitro settings must now be validated. Furthermore, a 
cell line containing the D620N mutation in the endogenous VPS35 gene would add 
validity to findings already reported using cells that have a VPS35 D620N construct 
stably overexpressed. Finally, characterization of the pathways perturbed by mutations in 
VPS35, is far from complete. A better understanding of the interplay of VPS35 and these 
pathways is required, so that therapeutic interventions can be crafted. 
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CHAPTER TWO: ENHANCED HYALURONAN SIGNALING AND AUTOPHAGY 
DYSFUNCTION BY VPS35 D620N 
The motor features of Parkinson’s disease result from loss of dopaminergic (DA) 
neurons in the substantia nigra with autophagy dysfunction being closely linked to this 
disease. A PD-causing mutation in VPS35 (D620N) has been reported to block 
autophagy. In order to identify signaling pathways responsible for this autophagy defect, 
we performed an unbiased screen using RNA sequencing (RNA-Seq) of wild-type or 
VPS35 D620N-expressing retinoic acid-differentiated SH-SY5Y cells. We report that 
VPS35  D620N-expressing cells exhibit transcriptome changes indicative of alterations in 
extracellular matrix (ECM)-receptor interaction as well as PI3K-AKT signaling, a 
pathway known to regulate autophagy. Hyaluronan (HA) is a major component of brain 
ECM and signals via the ECM receptors CD44, a top RNA-Seq hit, and RHAMM to the 
autophagy-regulating PI3K-AKT pathway. We find that high (>950 kDa), but not low 
(15 - 40 kDa), molecular weight HA itself can inhibit autophagy. In addition, VPS35 
D620N facilitated enhanced HA-AKT signaling. Transcriptomic assessment and 
validation of protein levels identified the differential expression of CD44 and RHAMM 
isoforms in VPS35 D620N mutant cells. Based upon this expression profile, these data 
suggest that the RHAMM isoform V3 may contribute to the enhanced activation of HA-
AKT signaling and autophagy inhibition by VPS35 D620N. 
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Introduction 
PD is a Progressive Neurodegenerative Disease 
In the USA, with a prevalence of 1% in people over 60 and over 4% by age 85, 
Parkinson’s disease is the most common disease of motor system degeneration (Lau & 
Breteler, 2006). This disease is clinically characterized by a resting tremor, rigidity, 
postural instability, and bradykinesia. PD’s primary motor features result from a loss of 
dopaminergic (DA) neurons in the substantia nigra pars compacta (SN) region of the 
midbrain. Specifically, the loss of dopamine produced by this neuronal subset causes 
dysfunction of the basal ganglia, a cluster of nuclei responsible for coordinating 
movement. No therapies to date deal with the underlying neuronal loss and thus only 
symptomatic treatments exist for PD (Jankovic & Stacy, 2007). 
Autophagy Misregulation in PD  
Macroautophagy (hereafter referred to as autophagy) is an orderly process of 
cytoplasmic engulfment by lipid membrane-bound vesicles termed autophagosomes 
leading to degradation of the encapsulated material (La Spada & Taylor, 2010). 
Autophagy proceeds in distinct steps that include induction, cargo recognition, 
autophagosome formation and transport, autophagosome-lysosome fusion, degradation of 
cargo, and the release of degraded material into the cytoplasm. Following the induction 
of autophagy, Atg8 (LC3) undergoes cleavage, and a Phosphatidylethanolamine(PE) 
moiety is conjugated (now LC3-II). LC3-II is unique to autophagosomes and is 
commonly used as a marker for autophagy (He & Klionsky, 2009). Autophagosomes fuse 
with endosomes and multivesicular bodies that in turn fuse with lysosomes containing 
lytic enzymes that facilitate the degradation of cargo. 
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Autophagy is primarily devoted to adapting to nutrient limitation, degrading 
misfolded proteins, and removing dysfunctional organelles (A. M. K. Choi, Ryter, & 
Levine, 2013). Studies of neurodegenerative disease and protein turnover pathways have 
indicated that the maintenance of protein quality control presents a particular challenge 
for neurons and other specialized cells of the nervous system (Malgaroli, Vallar, & 
Zimarino, 2006; J. P. Taylor, Hardy, & Fischbeck, 2002). This appears to be of particular 
importance to PD pathology as protein aggregates of α-synuclein are believed to be 
removed by autophagy, at least before fibril formation, and whose presence may signal 
autophagy dysfunction (Riedel, Goldbaum, Schwarz, Schmitt, & Richter-Landsberg, 
2010; Tanik, Schultheiss, Volpicelli-Daley, Brunden, & Lee, 2013). Moreover, 
inflammation and other proteotoxic insults can facilitate α-synuclein aggregation, perhaps 
by overloading the autophagic machinery with damaged proteins and organelles or by 
inhibiting autophagy directly. A link between PD and autophagy can also be traced 
genetically. For example, at least seven monogenic causes of PD strongly connected with 
autophagy regulation exist, and some are directly involved in lysosomal biology (Dehay 
et al., 2010, 2013). As a result, considerable effort has been made to understand 
autophagy dysfunction in PD, with the goal of targeting this process for therapy. 
The PD-Causing VPS35 D620N Mutation Affects Retromer Function and Blocks 
Autophagy 
In 2011, two independent groups reported the mutation of VPS35 (D620N) as 
being causal for a familial form of PD (Vilariño-Güell et al., 2011; Zimprich et al., 2011). 
VPS35 has a well-established and critical role in retromer function. The retromer is a 
highly conserved complex of proteins and an essential element of the endosomal sorting 
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machinery that directs the recycling of plasma membrane receptors. The retromer is 
comprised of a cargo recognition trimer containing VPS35-VPS29-VPS26 and a dimer 
made of an assortment of SNX1, SNX2, SNX5, and SNX6 (McGough & Cullen, 2011). 
This complex associates with endosomes and facilitates the retrograde transport of 
transmembrane cargo to the trans-Golgi network, thereby rescuing cargo from 
degradation by the lysosome. However, the mechanism for VPS35 D620N-mediated 
neurodegeneration remains unknown. 
Interest into the role of VPS35 in mediating autophagy was initially hinted at in 
work published by Dengjel et al where VPS35 was identified in an autophagosome-
interactor screen (Dengjel et al., 2012). Subsequently, Zavodszky et al., presented direct 
evidence of this by reporting that the PD-causing VPS35 D620N mutation impairs 
autophagy in HeLa cells through defective WASH complex recruitment to endosomes 
(Zavodszky et al., 2014). However, the study by Zavodszky et al. focused on members of 
the WASH complex—namely, canonical interactors of VPS35 (Gomez & Billadeau, 
2009; Hao et al., 2013). Interestingly, we did not detect an association with the principal 
WASH complex member WASH1 in retinoic acid (RA)-differentiated SH-SY5Y cells, a 
widely used cellular model of PD (Korecka et al., 2013; Krishna et al., 2014), suggesting 
the existence of distinct mechanism (Fig. S1). Therefore, we performed an unbiased 
transcriptome screen of RA-differentiated SH-SY5Y cells that we engineered to stably 
express VPS35 or VPS35 D620N using RNA sequencing. Our analysis has uncovered 
altered signaling in PI3K-AKT and extracellular matrix (ECM)-receptor interaction 
pathways. 
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Autophagy Regulation by Phosphatidylinositol-AKT Signaling  
Autophagy is regulated by two distinct kinase complexes: an autophagy-specific 
phosphatidylinositol 3-kinase   (PI3K) and mammalian target of rapamycin (mTOR)  
(Janku, McConkey, Hong, & Kurzrock, 2011). Members of the PI3K family 
phosphorylate phosphatidylinositol (PI) generating phosphatidylinositol 3-phosphate 
(PI3P) which serves as a docking lipid that can facilitate the complex formation and 
activation of proteins that include AKT. AKT then propagates this signal through a series 
of kinase events that result in suppression of autophagy. Our transcriptome screen 
revealed this pathway as a top hit affected by VPS35 D620N, suggesting it could be a 
major effector for autophagy blockade. 
HA-AKT Signaling  
The major structural component of brain extracellular matrix (ECM) is 
hyaluronan (HA), which not only serves as the main anchoring point for brain cells but is 
also an important facilitator of intracellular signaling. CD44 and RHAMM are primary 
receptors for HA that signal to AKT upon binding (Lin, Chang, & Ying, 2007; Onodera, 
Teramura, Takehara, & Fukuda, 2015; Trapasso & Allegra, 2012, p. 44). Our RNA-Seq 
data indicates that VPS35 D620N causes altered extracellular matrix receptor interaction 
and suggests dysregulated PI3K-AKT signaling. Interestingly, while studies have been 
reported showing HA, CD44 and RHAMM activation of the autophagy modulators AKT 
and mTOR there are no reports directly addressing HA regulation of autophagy. We then 
hypothesized that perturbed HA-AKT signaling may contribute to VPS35 D620N 
autophagy dysfunction. 
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Results 
VPS35 D620N Inhibits Autophagy 
To determine whether VPS35 D620N represses autophagy in a PD model system, 
we first engineered a human neuroblastoma cell line (SH-SY5Y) to stably express WT or 
D620N VPS35 (V5–tagged). This was done by obtaining a VPS35-expressing lentivirus 
construct from Lynda Chin (Scott et al., 2009) and generating the D620N mutation by 
site-directed mutagenesis. We next infected low passage SH-SY5Y cells (ATCC) and 
selected transgene-positive cells using blasticidin. Before conducting experiments, we 
differentiated SH-SY5Y cultures into post mitotic dopaminergic neuron-like cells using 
10uM retinoic acid for 7 days. Western blot revealed that WT and D620N transgenic 
proteins are expressed equally and at a similar level to endogenous VPS35 (Fig. 2.1A). In 
stable cell lines, no endogenous VPS35—only transgenic (shifted) VPS35—was 
detected, which is likely due to transgenic VPS35 titrating out endogenous VPS35 from 
the retromer complex. The knockdown of VPS35 results in the knockdown of the other 
core retromer component members (VPS29) and vice versa, suggesting that free VPS35 
as well as VPS29 are rapidly degraded by the cell (Fig. 2.2C) (Fuse et al., 2015). 
Therefore, serendipitously, these cell lines express the transgene at endogenous protein 
levels, thereby avoiding overexpression artifacts. Upon examination of autophagy in 
these cells, we found autophagy to be robustly inhibited by D620N, as evidenced by the 
reduced LC3-II induction following Bafilomycin A1 treatment (Figs. 2.1B and 2.1C). 
We further tested autophagy dysfunction by VPS35 D620N through assessing the 
clearance of intracellular alpha-synuclein aggregates (Fig. S2) (Outeiro et al., 2008). We 
report that mutant-expressing cells accumulated significantly higher levels of alpha-
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synuclein aggregates which supports the notion that VPS35 D620N is a potent inhibitor 
of autophagy. 
 
Figure 2.1 VPS35 D620N inhibits autophagy.  
Transgenic and endogenous VPS35 were evaluated using western blot (A). Differentiated 
SH-SY5Y cells stably expressing transgenic VPS35 (WT or D620N) were treated with 
Baf A1 to block autophagosome/lysosome fusion. Western blot of LC3-II was performed 
(B) and autophagic flux quantified (C). Results from three independent experiments are 
displayed (*P<0.05 compared to indicated group, student’s t-test; error bars = SEM). 
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Figure 2.2 VPS35 knockdown inhibits autophagy.  
VPS35 expression was knocked down in differentiated SH-SY5Y cells neurons by two 
distinct lentivirus-delivered shRNA vectors. Following selection with puromycin, cells 
were treated with Baf A1 to block autophagosome/lysosome fusion. Western blot of 
LC3-II was performed (A) and autophagic flux quantified (B). Results from three 
independent experiments are shown (*P<0.05 versus indicated group, student’s t-test; 
Error bars = SEM). Knockdown of VPS29 by shRNA using a lentiviral vector was also 
performed (C). 
 
VPS35 Knockdown Inhibits Autophagy, Phenocopying the VPS35 D620N Mutation. 
To determine if the D620N mutation elicited autophagy blockade through a loss 
of function in differentiated SH-SY5Y cells, we knocked down VPS35 expression using 
two distinct shRNA constructs delivered by lentivirus and assessed autophagy (Fig. 2.2A 
and B). We found that VPS35 knockdown resulted in repression of autophagy consistent 
with VPS35 D620N being a loss-of-function mutation. As reported by other groups, we 
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found that knockdown of other core retromer components such as VPS29 by shRNA 
resulted in concomitant knockdown of VPS35 (Fig. 2.2C) (Fuse et al., 2015). Therefore, 
it was not surprising to observe that VPS29 knockdown also suppressed autophagy. 
Collectively, these data suggested that VPS35 D620N is a loss-of-function mutation, 
which ultimately suppresses autophagic activity. 
VPS35 D620N Misregulates ECM-Receptor Interaction and Pi3k-AKT Pathway Gene 
Expression 
Having established autophagy dysfunction by VPS35 D620N, likely through a 
loss-of-function, we next sought to determine a precise molecular mechanism for this 
phenomenon. To this end, we performed RNA sequencing of the transcriptomes of 
transgenic WT and D620N VPS35-expressing SH-SY5Y cells. Gene ontology was 
performed (1.5 fold change cutoff) using iPathways (Advaita) and KEGG annotated 
pathways were assigned to gene expression changes (Luo, Friedman, Shedden, 
Hankenson, & Woolf, 2009; Mootha et al., 2003; Subramanian et al., 2005). Top pathway 
hits were ECM-receptor interaction and PI3K-AKT signaling which suggests that ECM 
signaling is perturbed by VPS35 D620N (Table 1). Examination of specific transcripts 
altered for ECM-receptor interaction and PI3K-AKT KEGG annotated pathways reveals 
that CD44 mRNA expression is misregulated in VPS35 D620N cells (Fig. 2.3).
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Table 2.1.  ECM-receptor interaction and AKT pathway perturbation by VPS35 
D620N.  
RNA-Seq was performed on WT and VPS35 D620N-expressing SH-SY5Y cells. The top 
5 pathways affected by VPS35 D620N expression and relevant significance values are 
listed. 
Pathway name Pathway 
ID 
p-value p-value 
(FDR) 
p-value 
(Bonferroni) 
Pathways in cancer 05200 9.878e-8 2.683e-5 2.914e-5 
Systemic lupus 
erythematosus 
05322 1.819e-7 2.683e-5 5.367e-5 
ECM-receptor 
interaction 
04512 2.294e-6 2.256e-4 6.768e-4 
PI3K-AKT signaling 
pathway 
04151 3.124e-6 2.304e-4 9.215e-4 
Focal adhesion 04510 9.627e-6 5.680e-4 0.003 
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Figure 2.3.  Transcriptome alteration of ECM-receptor and PI3K-AKT pathways 
by VPS35 D620N.  
Specific transcript expression changes (Log-Fold-Change) for ECM-receptor interaction 
(Top) and PI3K-AKT signaling (Bottom) KEGG pathways from RNA-Seq data are 
shown. The distribution of all gene perturbations in the pathway are represented in the 
box plot where the first, median and third quartile are indicated. 
 
 
26 
 
 
Hyaluronan Inhibits Autophagy in Differentiated SH-SY5Y Cells 
Our findings from RNA-Seq data indicate that HA-AKT signaling is perturbed in 
the VPS35 mutant cell line. These results pose the novel question of whether the HA-
AKT signaling axis controls autophagic response. To test this directly, we added HA at 
concentrations reported to elicit biological effects in human monocytes and fibroblasts to 
differentiated SH-SY5Y cells (Maharjan, Pilling, & Gomer, 2011). We chose to treat 
cells with either high (HMW) or low molecular weight (LMW) HA since the polymer 
size can direct divergent bioactivities (Maharjan et al., 2011). We observed a dose-
dependent repression of autophagy following treatment with HMW but not LMW HA 
(Fig. 2.4). This is the first report of HA modulating autophagy and may indicate that the 
composition of ECM is an important factor in the regulation of this key process. 
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Figure 2.4.  HA inhibits autophagy.  
RA-differentiated SH-SY5Y cells were treated with high molecular weight (>950 kDa) 
HA in serum-free media for 24 hours. The next day, cells were treated with or without 
Baf A1 and autophagic flux assessed by LC3-II/β-Actin western blot (A) and quantified 
from three experiments (B). Similarly, low molecular weight (15 - 40 kDa) HA treatment 
was performed and autophagic response evaluated by LC3-II/β-Actin western blot (C) 
and represented graphically (D) (*P<0.05 versus indicated group, student’s t-test; Error 
bars = SEM).  
 
 
 
 
 
 
 
28 
 
 
Altered Hyaluronan-AKT Signaling by VPS35 D620N  
We next examined whether VPS35 D620N-expressing cells exhibited heightened 
sensitivity to HA. Addition of HMW HA resulted in elevated AKT activation in mutant 
cells (Fig. 2.5A). Conversely, low molecular weight HA failed to induce AKT activation 
in either WT or mutant cells (Fig. 2.5B). This suggests that VPS35 D620N facilitates 
enhanced HMW HA signaling. These results are also consistent with our findings that 
HMW and not LMW HA repress autophagy via canonical HA-AKT signaling.  
 
Figure 2.5.  Elevated HA signaling by VPS35 D620N.  
Differentiated SH-SY5Y cells expressing wild-type (WT) or D620N VPS35 were serum-
deprived overnight. The following day, high molecular weight (>950 kDa) HA (300 
ug/mL) (A) or low molecular weight (15 - 40 kDa) HA (300 ug/mL) (C) was added for 
the indicated times and western blotting was then performed (p-AKT = Ser473). Results 
are presented as a ratio of D620N/WT for p-AKT/β-Actin by western blot band 
densitometry for each time point shown (B, D) (*P<0.05 versus indicated group, 
student’s t-test; Error bars = SEM). 
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AKT Pathway Activation by VPS35 D620N is Independent of Hyaluronan Production  
To determine whether HA production contributes to heightened AKT signaling in 
VPS35-D620N cells, we measured HA produced during a 48h period (Fig. 2.6), but 
found no detectable difference in wild-type and mutant cells. We also assessed the 
protein levels for the hyaluronan synthase (HAS) enzymes responsible for HA synthesis. 
HAS3 was not differentially expressed while we were unable to detect HAS1 and HAS2 
in SH-SY5Y cells (Fig. 2.7A). Taken together, these findings suggest that enhanced HA 
production is not responsible for the observed change in AKT signaling for VPS35 
D620N-expressing cells.  
   
Figure 2.6.  VPS35 D620N does not affect HA production.  
ELISA detection of HA (all forms, >35kDa) production in cell culture supernatant (over 
48h in 0.5% FBS-containing media) from differentiated wild-type and mutant SH-SY5Y 
cells (results from three independent experiments; student’s t-test; P>0.05; Error bars = 
SEM). 
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Figure 2.7.  VPS35 D620N alters CD44 and RHAMM protein expression.  
Western blot of differentiated SH-SY5Y cells expressing wild-type (WT) or D620N 
VPS35. Visualization of CD44 protein required 60-80ug total lysate and ECL Plus 
reagent (A). RHAMM protein detection was done using 10ug of total lysate and standard 
ECL reagent (B). 
 
Misregulated CD44 and RHAMM Expression by VPS35 D620N 
Our RNA Seq analysis revealed that ECM-receptor interaction pathways were a 
top hit for VPS35 D620N-expressing cells (Table 2.1). From this dataset we also found 
that CD44 transcript expression increased significantly in VPS35 D620N-expressing 
cells. Consistent with CD44 pathway misregulation, assessment of protein expression 
revealed heightened CD44 expression in the mutant cells (Fig. 2.7A). Interestingly, only 
a single truncated isoform of CD44 protein was observed that correlated to CD44v4. 
Identity of CD44v4 was confirmed by further analysis of the RNA Seq data. What’s 
more, CD44v4 was very lowly expressed at both the protein level, requiring 60-80ug of 
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total lysate and a sensitive ECL reagent (WesternSure) to detect, and RNA level, nearing 
the limit of accurate detection in our RNA-Seq dataset (Table 2.2). These factors led us 
to speculate that CD44 likely provides only a minor contribution to HA signaling in SH-
SY5Y cells. We then examined the protein levels of RHAMM, another primary receptor 
for HA, and found robust expression of multiple isoforms. However, RHAMM isoform 3 
(RHAMMv3) protein was strikingly absent from VPS35 D620N-expressing cells (Fig. 
2.7B). The identities of all four NCBI annotated isoforms were confirmed at the 
transcript level by RNA-Seq data. Collectively, these data suggest that the RHAMMv3 
may contribute to the enhanced activation of HA-AKT signaling and autophagy 
inhibition by VPS35 D620N mutation, with minor contributions from CD44 
misregulation. 
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Table 2.2.  VPS35 D620N affects CD44 and RHAMM RNA splice variant 
expression. 
SpliceR program analysis was performed on the WT and VPS35 D620N RNA-Seq 
dataset. Relative expression profiles are presented for all NCBI annotated splice variants 
as a function of FPKM for CD44 (A) and RHAMM (B). Significance for differential 
expression by WT versus D620N is shown. 
 
(A) 
Isoform Ref. Seq. Rel. Exp. 
WT 
Rel. Exp. 
D620N 
WT/D620N 
Ratio 
p-value 
V1 NM_000610 0.0000 0.0000 INF 1 
V2 NM_001001389 0.0000 0.0142 0 1 
V3 NM_001001390 0.0000 0.0000 INF 1 
V4 NM_001001391 0.3387 1.0256 0.3303 0.0452 
V5 NM_001001392 0.1853 0.0000 INF 1 
V6 NM_001202555 0.0000 0.0256 0 1 
V7 NM_001202556 0.0000 0.0004 0.0954 1 
V8 NM_001202557 0.0444 0.0000 INF 1 
 
(B) 
Isoform Ref. Seq. Rel. Exp. 
WT 
Rel. Exp. 
D620N 
WT/D620N 
Ratio 
p-value 
V1 NM_001142556.1 5.1525 5.5884 0.9220 0.6159 
V2 NM_012484.2 0.9834 0.3711 2.6500 0.3170 
V3 NM_012485.2 13.5848 13.0535 1.0407 0.6639 
V4 NM_001142557.1 1.4806 0.6353 2.3306 0.2983 
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Discussion 
The study of monogenic causes of PD has yielded valuable insights into the 
pathogenesis of this disease. The identification of VPS35 D620N as a causal familial 
factor has allowed for the molecular dissection of signaling pathways that could be 
important therapeutic points for this and other forms of PD. It is well-established that 
VPS35 D620N inhibits autophagy and that this mutation also hinders retromer function 
(Follett et al., 2014b; McGough et al., 2014; Zavodszky et al., 2014). Accordingly, 
research focus in the field has been placed upon canonical retromer interactors and 
pathways. This approach might be limiting as our group’s inability to confirm WASH 
complex-retromer interaction in SH-SY5Y cells suggests. Therefore, in an effort to assay 
all potentially relevant signaling pathways we have created isogenic transgenic SH-SY5Y 
cell lines expressing VPS35 or VPS35 D620N and performed RNA Seq transcriptome 
analysis. 
Identification of perturbed HA-AKT signaling as a contributor to VPS35 D620N-
mediated autophagy dysfunction may offer a therapeutic target for PD as well as broaden 
the understanding of autophagy regulation. We report for the first time to the authors’ 
best knowledge that HMW HA serves as a negative regulator of autophagy. Given the 
high concentration of HMW HA in the mammalian brain, the physiological consequences 
of this finding could be far-reaching. In the scope of neurological disease, defective 
autophagy is linked to a wide variety of maladies (Levine & Kroemer, 2008). If HMW 
HA and autophagic activity are coupled, then one could imagine that the concentration 
and quality of HMW HA might guide the path of neurodegenerative disease particularly 
as we age and are less adept at maintaining ECM. In the context of PD, recognition of 
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HA-AKT pathway involvement in the misregulation of autophagy in catecholaminergic 
cells could provide a novel target for treatment. 
Our discovery that VPS35 D620N-expressing cells have heightened response to 
HMW but not LMW HA indicates that HA-AKT signaling is not initiated by a traditional 
ligand-receptor mechanism. This finding would imply that the responsible HA receptor(s) 
require scaffolding to a large ECM structure for activation. Previous work has indeed 
shown that cytoarchitecture is important for HA signaling (Neame, Uff, Sheikh, 
Wheatley, & Isacke, 1995). Maharjan and colleagues have specifically explored the 
signaling divergences between HMW and LMW HA (Maharjan et al., 2011). During 
remodeling, such as following injury, HMW HA is broken down to LMW by matrix 
metalloproteinases (MMP). This group reported that environments can direct monocyte 
differentiation and activation based upon HA polymer size. It is therefore not 
inconceivable that brain HA composition could serve a similarly important function.  
CD44 and RHAMM are the most researched HA receptors. These proteins have 
largely been studied in the context of cancer metastasis due to being refined sensors for 
detecting the state of ECM for an invading cancer cell (Savani et al., 2001, p. 44). Upon 
identifying defective HA-AKT signaling we examined CD44 and RHAMM expression. 
We report that SH-SY5Y cells express only a single isoform (V4) of CD44 (CD44v4) 
protein, albeit at very low levels, and that this isoform is found in higher amounts in 
mutant versus control cells. We also found that CD44v4 protein and mRNA levels 
correlate closely. However, the extremely low level of CD44 expression coupled with the 
observation that the CD44 protein expression is likely controlled largely by 
transcriptional mechanisms suggest that CD44 plays a minor role in VPS35 D620N 
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dysfunction. In contrast, RHAMM protein is abundantly expressed yet isoform V3 
(RHAMMv3) is strikingly absent from VPS35 D620N-expressing cells. Interestingly, 
RHAMMv3 transcript levels are indistinguishable for the wild-type and mutant cells 
indicating post-splicing regulation of expression and potentially a direct role for VPS35. 
Taken together, these data suggest that the RHAMMv3 may contribute to the enhanced 
activation of HA-AKT signaling and autophagy inhibition by VPS35 D620N. 
The receptor for hyaluronan-mediated motility, RHAMM, is expressed on the cell 
surface as well as intracellularly. RHAMM was shown to associate with cytoskeletal 
components (Assmann, Jenkinson, Marshall, & Hart, 1999) in addition to the mitotic 
spindle (Christopher A. Maxwell et al., 2003) and direct numerous processes including 
mitosis and tumorigenesis (Christopher Alan Maxwell, McCarthy, & Turley, 2008; 
Mohapatra, Yang, Wright, Turley, & Greenberg, 1996). Thus, the study of this protein 
has been of particular interest in the context of cancer. Interestingly, Sohr et. al. 
demonstrated that overexpression of a tumor suppressor p53 mutant that lacks DNA-
binding ability results in a specific loss of the RHAMMv3 isoform in DLD-1 cells (Sohr 
& Engeland, 2008). This group and others have also shown that p53 regulates 
transcription of the RHAMM gene (Schütze et al., 2016; Sohr & Engeland, 2008). 
Specific functionality of RHAMMv3 is also suggested from clinical data indicating that 
the RHAMMv3:RHAMMv1/v2 ratio is associated with a poor prognosis for multiple 
myeloma (Christopher A. Maxwell et al., 2004) and non-small cell lung carcinoma (D. 
Wang et al., 2016). It is important to note that RA-differentiated SH-SY5Y cells are post-
mitotic so aberrant p53 activity would result from genomic instability or inappropriate 
signaling that is not a direct result of the cell cycle. Our RNA Seq data reveals cancer 
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signaling through focal adhesion or growth factor receptors as the top overall hit for 
altered signaling by VPS35 D620N. It is therefore not unreasonable to hypothesize that 
this perturbed signaling mediated by VPS35 D620N affects p53 activity which might in-
turn lead to repression of RHAMMv3 expression. Further investigation into a HA-
RHAMM-p53-VPS35 signaling axis could provide valuable insights into PD and cancer. 
In summary, we report that VPS35 D620N suppresses autophagy in RA-
differentiated SH-SY5Y cells in a manner consistent with a loss of function mutation. 
Using an unbiased RNA Seq screen, we identified misregulated ECM-receptor and PI3K-
AKT signaling pathways in the mutant cells. Subsequent investigation revealed enhanced 
HMW HA-AKT signaling with an expression defect in a single isoform of RHAMM 
(RHAMMv3) being a likely contributing factor. These results provide a compelling 
rationale to further investigate ECM dynamics in PD and other neurological disorders. 
Methods 
Tissue Culture  
SH-SY5Y human neuroblastoma cells (ATCC) were cultured in T175 tissue 
culture flasks and maintained at 37°C with 5% CO2 environment. Cells were cultured in 
DMEM/F12 50/50 media (Corning) with L-glutamine, 15% Fetal Bovine Serum (Atlanta 
Biologicals), 1% non-essential amino acids, 1% penicillin/streptomycin solution 
(Hyclone, 10000 units/mL Penicillin/10000µg/mL Streptomycin). Cells were passaged 
when flasks reached ~80% confluency using 0.25% Trypsin, with 2.2mM EDTA and 
sodium bicarbonate (Corning). Cells at passage numbers 8 thru 15 were used for 
experiments. For this, cells were plated on multi-well tissue culture plates at the 
necessary cell concentrations (e.g., 4 million cells per well on a 6-well plate). Prior to 
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experimentation, the cells were treated with retinoic acid for 7 days, to differentiate them 
into post-mitotic catecholaminergic neuron-like cells. Transgenic cells were also treated 
72h prior to experimentation with 2mM sodium butyrate to reactivate transgene 
expression (K. H. Choi, Basma, Singh, & Cheng, 2005). 293TA cells were grown in 
DMEM media with 1.0 g/L Glucose, with L-glutamine and with Sodium Pyruvate 
(VWR), supplemented with 10% Fetal Bovine Serum (Atlanta Biologicals), 1% non-
essential amino acids (Corning Cellgro) and 1% penicillin/streptomycin solution 
(Hyclone, 10000 units/mL Penicillin/10000µg/mL Streptomycin). 
Western Blotting 
Life Technologies Bolt gels and reagents were used for western blotting. Cells 
were lysed using RIPA lysis buffer containing a protease inhibitor cocktail and then 
sonicated. This was then followed by centrifugation at 15000g for 10 minutes and 
collecting supernatant. Total protein levels were measured and normalized across 
samples. Polyacrylamide gel electrophoresis was performed on the protein extracts 
followed by transfer onto a PVDF membrane. Transfers to PVDF membranes were 
performed using the iBlot2 Dry Transfer device (Life Technologies). Primary antibodies 
were used to detect LC3 (Novus Biologicals, NB100-2220), CD44 (Origene, TA506726), 
Phospho-AKT (Ser 473) (Cell Signaling, 4060), RHAMM (Genetex, GTX54121) and β-
actin (Thermo Fisher, MA1-91399). Secondary antibodies (anti-mouse, Cell Signaling, 
7076; anti-rabbit, Cell Signaling, 7074) were used for probing PVDF membranes after 
primary antibody incubation. ECL substrate (Pierce, 32106) or, for more sensitive 
detection, WesternSure chemiluminescent substrate (LI-COR, 926-95000) was then used 
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to visualize protein bands and images obtained with a ChemiDoc Touch Gel Imager 
(BioRad). Protein expression was quantified by densitometry using Image J (NIH). 
Lentivirus Production and Transduction  
Life Technologies Virapower lentiviral production kit was used to generate 
lentivirus. 293TA cells (GeneCopoeia) were transfected with plasmids using 
Lipofectamine 2000 (Life Technologies). Media was replaced the next day. The 
supernatant media containing active, fully assembled lentiviruses, was collected 48 hours 
after transfection and filtered through 400 nm pore filters, aliquoted and stored at -80°C 
until use. For transduction of SH-SY5Y cells, virus containing supernatant was added 
directly to the culture media. This media was replaced the next day and antibiotic 
selection (blasticidin or puromycin) for transduced cells was initiated 72 hours following 
viral supernatant addition. 
Autophagic Flux Assay 
Bafilomycin A1 (100nM) was used to block autophagy in experimental cells, four 
hours prior to lysis. This was then followed by comparison of LC3-II levels normalized 
to β-Actin between bafilomycin A1 treated and untreated cells obtained from western blot 
imaging as previously described (Klionsky et al., 2012). 
Hyaluronan Treatment  
Cells were plated at a density of 4 million cells per well on 6 well plates. Cells 
were then differentiated with RA for 7 days. On the day prior to lysis, cells were treated 
with high or low molecular weight HA in serum-free media and then lysed using RIPA 
lysis buffer, as described above. For autophagic flux assays, cells were treated with or 
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without HA in the presence or absence of Bafilomycin A1 (100nM) for 4 hours 
immediately prior to lysis and then autophagic flux assessed as described above. 
Hyaluronan Quantification 
ELISA measurement of Hyaluronan was performed using a Quantikine ELISA kit 
(R&D Systems, DHYAL0) according to the manufacturer’s instructions. Briefly, cells 
were plated on 96 well plates at 50,000 cells/well. The cells were then treated with 
retinoic acid media for seven days. After differentiation, the media was replaced with 
growth media containing 0.5% FBS and RA. Supernatant was then collected after 48 
hours for ELISA analysis. It should be noted that this ELISA system detects all forms of 
HA (>35kDa). 
Differential Gene Expression, Splicing and Gene Set Enrichment Analysis 
Transgenic WT and VPS35 D620N-expressing cells grown in 100mm culture 
plates were RA-differentiated, RNA was extracted using an RNeasy kit (Qiagen) with 
DNase treatment, rRNA depleted, random-primed cDNA made, and sequencing 
subsequently performed using Illumina with HiSeq2000/2500 (>40 million 
reads/sample). Sequencing and analysis were done by Idaho State University’s Molecular 
Research Core Facility. Alignment of mRNA-Seq was conducted with a standard 
protocol as previously described (Trapnell et al., 2012). Briefly, raw reads were initially 
trimmed with FASTX-toolkit to remove adapter sequences, and aligned to a reference 
genome (human hg19) with TopHat (v2.0.11). To take into account novel splice 
isoforms, the de novo transcript assembly from the mapped reads was performed using 
cufflinks (v2.2.1) and the assembled transcripts were then merged into a single reference 
transcripts using cuffmerge. The resulting full length, mapped transcripts were further 
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analyzed using a Bioconductor package, spliceR (Vitting-Seerup, Porse, Sandelin, & 
Waage, 2014), and investigated the alternative splicing events of individual genes. 
For differential gene expression analysis, the mapped reads were quantified using 
cuffdiff and calculate the FPKM (Fragments Per Kilobase of transcript per Million 
mapped reads). Genes were discarded from downstream analysis when the calculated 
mRNA abundance was lower than FPKM of 0.5, treating them as background noise. The 
quantified results were further visualized with CummeRbund (Trapnell et al., 2012) or 
custom scripts in R. To investigate whether the expression level of pre-defined sets of 
genes correlated to the observed phenotype, the Impact Analysis method was conducted 
using iPathwayGuide (Advaita)(Draghici et al., 2003; Khatri, Draghici, Tarca, Hassan, & 
Romero, 2007; Tarca et al., 2009). The number of gene-set permutations was set at 1000, 
and the most enriched KEGG gene sets (Kanehisa et al., 2014) were selected based on 
Normalized Enrichment Scores (NES). 
Gaussia Luciferase Protein-Fragment Complementation Assay 
Plasmids containing transgenic fusion constructs of syn-hGluc (SynLuc), syn-
hGLuc1 (S1) and syn-hGLuc2 (S2) were transfected (40ng DNA/well) into transgenic 
(WT or VPS35 D620N) SH-SY5Y cells in 96 well plates using FuGENE 6 (Promega, 
E2691) according to manufacturer’s instructions as previously described (Outeiro et al., 
2008). Media (conditioned media) was transferred to a new 96 well plate 48 hours later 
for analysis. The cells were then washed with PBS and new media (without phenol red or 
FBS) added. Aggregation of alpha-synuclein was determined by assessing 
complementation of luciferase activity. Luciferase activity was measured within the 
conditioned media and living cells by automated injection of coelenterazine (40 µM, 
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P.J.K., 55779-48-1) into each well and detected using a plate reader (Victor X3 
microplate reader, Perkin-Elmer) with a 1 second signal integration time. 
Statistical Analysis and Data Management 
Statistical analysis was performed using Prism (version 6.0; GraphPad Software, 
San Diego, CA). Data between two variables was based on the student’s t-test. Data was 
considered significantly different at p < 0.05. The datasets generated during and/or 
analyzed during the current study are available from the corresponding author upon 
request. 
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Supplementary Figures 
 
Figure S1.  WASH1-VPS35 interaction is not detected in SH-SY5Y cells.  
Non-transgenic (SH-SY5Y), WT-VPS35, and VPS35-D620N-expressing SH-
SY5Y cells were RA-differentiated and then WASH1-VPS35 interaction assessed with 
co-immunoprecipitation (IP) by pulling transgenic VPS35 down with a V5 antibody. The 
blot was then subjected to western blotting with the indicated antibodies (> denotes the 
VPS35 band; * signifies a non-specific band found in all samples). Whole cell lysates 
(WCL) were also included. Successful VPS35 IP was verified by co-immunoprecipitation 
of known interactors VPS29, VPS26, and TBC1D5. As reported by other groups, we do 
not observe differential interaction of retromer members (VPS29 and 26A) by VPS35 
D620N. 
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Figure S2.  VPS35 D620N enhances intracellular alpha-synuclein aggregation.  
WT or VPS35 D20N-expressing SH-SY5Y cells were transfected with S1 and S2 
plasmids containing full-length alpha-synuclein fused to N-or C-terminal parts of human 
Gaussia luciferase. Upon aggregation of alpha-synuclein, complementary portions of 
luciferase produced a functional enzyme that was detected by adding luciferase substrate 
coelenterazine. Full length luciferase as well as alpha-synuclein conjugated to full-length 
luciferase were also examined as basal expression controls. VPS35 D620N-expressing 
cells exhibited significantly elevated alpha-synuclein aggregation compared to WT cells 
(student’s t-test; **P>0.05; Error bars = SEM). 
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Figure S3.  RNA-Seq data assessment.  
Alignment statistics for sequencing reads (A). mRNA abundance distribution 
(density plot) for all genes quantified from RNA-seq analysis (B). Each replicate was 
plotted individually and overlaid to show there is no distribution bias. FPKM ≥ 0.5 was 
arbitrary set as cut-off value for downstream analysis. A scatter plot comparing wild-type 
(wt) and VPS35-D620N (mut) samples (C). Each dot represents the average expression 
level (FPKM) of individual genes calculated from three biological replicates. The vast 
majority of genes were expressed similarly in wt (VPS35) and mut (VPS35-D620N) 
cells, but genes that were differentially expressed are remotely located from the diagonal 
dashed-line. A dendrogram of all quantified mRNA from RNA-seq analysis (D). 
Clustering among biological replicates suggested that the D620N mutation causes 
differential gene expression.  
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Nestin-Positive/Sox2-Negative Cells Mediate Adult Neurogenesis of Nigral 
Dopaminergic Neurons in Mice 
Citation: Albright, J. E., Stojkovska, I., Rahman, A. A., Brown, C. J., & Morrison, B. E. 
(2016). Nestin-positive/SOX2-negative cells mediate adult neurogenesis of nigral 
dopaminergic neurons in mice. Neuroscience Letters, 615, 50–54. 
http://doi.org/10.1016/j.neulet.2016.01.019 
Introduction 
Parkinson’s disease (PD) is the most common motor disorder and the second most 
prevalent neurodegenerative disease. PD motor dysfunction (rigidity, tremor, 
bradykinesia, and postural instability) results from loss of dopaminergic (DA) neurons in 
the substantia nigra (SN). However, a basic understanding of the mechanism for DA 
neuron loss remains elusive. Consequently, only symptomatic treatments exist for PD and 
none that address the underlying neurodegeneration. Determining whether DA neurons 
are replenished in the adult SN is fundamental to understanding the loss of these neurons 
during PD. One possibility is that suppression of adult DA neurogenesis could be a 
driving force toward PD. Additionally, exploiting endogenous neurogenesis could offer 
potential avenues for therapy as well as better inform stem cell transplantation efforts.  
Deficiencies in the process of adult neurogenesis have been strongly associated 
with Alzheimer’s disease (AD), a neurodegenerative disorder sharing many 
epidemiological features with PD. Hippocampal neurons responsible for memory 
processing are preferentially lost in AD and evidence suggests this may be due, in part, to 
decreased neurogenesis (reviewed in [1]). Hippocampal adult neurogenesis occurs at a 
high rate throughout life but appears to decrease sharply in human AD as well as mouse 
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models of the disease. Interventions that promote adult neurogenesis improve preclinical 
model outcomes for histopathology as well as functionality. Neurogenesis of 
hippocampal neurons in adult humans and rodents begin from stem cell (SC) populations 
residing in the subgranular zone (SGZ) of the dentate gyrus.  SC populations are 
relatively less differentiated and possess replicative capacity. Therefore, these cells can 
regenerate the SC pool as well as contribute progeny that can differentiate into neuronal 
precursor cells (NPCs) that are post-mitotic and committed to neuronal fates.  
In addition to hippocampal neurons, olfactory neurons are replenished throughout 
the life of primates and rodents. SCs responsible for this process reside in the 
subventricular zone (SVZ). Once born, NPCs migrate a considerable distance to the 
olfactory bulb before integration and final differentiation into functional neurons. 
Currently, the SGZ and SVZ are the only known locations for SC generation in the adult 
mammalian brain. However, whether NPC pools reside elsewhere or transdifferentiation 
to NPCs from existing cell types occur remains to be determined.  
The evidence for a contribution of adult neurogenesis to PD is inconclusive. 
Reduced proliferation of SVZ cells has been reported in human PD [2,3]. Additionally, a 
number of studies have reported that wide-spread overexpression of a protein known to 
be a monogenic cause of rare forms of PD, alpha-synuclein (WT, A53T, E46K, and 
A30P), in mice results in inhibition of neurogenesis in the SGZ and SVZ [4-8].   
Moreover, transgenic mouse overexpression of PD-causing mutations in leucine-rich 
repeat kinase 2 (LRKK2) hinder proliferation and survival of SCs in the SVZ and SGZ 
[9]. However, a major caveat is that none of these mouse models induce DA neuron loss 
in the SN so the relevance to DA neurogenesis or even PD is debated. Administering the 
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PD model neurotoxins 6-OHDA or MPTP in rats or mice, respectively, does target DA 
neurons and inhibition of SC generation in the SVZ has been reported [2,10,11]. 
Conversely, other groups have reported increased neurogenesis following MPTP 
treatment [12]. In any event, the DA neuron loss in these models is rapid, easily 
achieving 80-100% loss within two weeks. Such a speedy loss does not mirror human 
progressive PD and cannot be explained by suppression of neurogenesis making 
connections between PD and this process using these neurotoxins dubious.  
Attempts have been made to monitor adult DA neurogenesis in the SN directly 
using various cell lineage tracing methods with conflicting results [13-15]. Lack of 
compelling evidence for DA neurogenesis has reinforced the prevailing notion that the 
presence of a toxic stimulus or trophic factor withdrawal induces mature DA neurons to 
undergo death in a slow and progressive manner. Therefore, while still controversial, the 
predominate viewpoint is that stem cell replacement of adult DA neurons in the SN does 
not occur at appreciable levels [13]. The most prevalent method of DA neuron lineage 
tracing utilizes DNA incorporation of the thymidine analog bromodeoxyuridine (Brd-U) 
or similar reagent to monitor for cell division of SCs. This method is problematic for a 
number of reasons. Firstly, Brd-U is quite toxic to the organism and to dividing cells. 
Secondly, Brd-U can yield false-positive results for cells undergoing DNA repair. 
Additionally, these regimens of Brd-U use are adopted from studies focused in regions of 
the brain exhibiting high levels of neurogenesis such as the hippocampus. Moreover, use 
of this chemical requires double-immunolabeling for the DA neuron marker tyrosine 
hydroxylase (TH) and Brd-U. Resolution of double-positive cells requires great care 
using confocal microscopy and issues have been reported [15]. This method is also not 
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readily amenable to large sample numbers. Another common method of lineage tracing is 
by injection of retrovirus to permanently label SCs and NPCs. However, this requires 
knowledge of the precursor cell location which is currently unknown. The aim of this 
study was to overcome these limitations by employing a novel system that utilizes a drug 
that could be administered for 6-8 weeks without severe health complications, extends 
the post-labeling duration, and allows for accurate quantitation of DA neurons in the SN 
of mice by single-labeling. 
Methods 
All husbandry and study procedures involving mice were performed in 
accordance with Boise Veterans Affairs Medical Center Institutional Animal Care and 
Use Committee guidelines. Thlox mice [16] were kindly provided by Drs. Richard 
Palmiter and Martin Darvas at The University of Washington. The nestin-CREERT2 [17] 
and Sox2-CREERT2 [18] mouse lines were obtained from The Jackson Laboratory. Mice 
were fed ad libitum and maintained on 12hr light/dark cycles. For tamoxifen treatment, 
three-month-old mice were provided 400mg/kg tamoxifen citrate chow (Envigo) as sole 
food source for 6 weeks. Mice were then placed back on standard rodent chow for the 
remainder of the study. 
For Immunohistochemistry (IHC), mice (n = 6 per group) were anesthetized with 
5% isoflurane and transcardially perfused with 10mL 0.1M phosphate buffer (PB) (pH 
7.2) with 1mM EDTA followed by 10mL 4% paraformaldehyde (PFA) in PB. Brains 
were harvested and then fixed in 4% PFA for 24h at 4°C. Next, brains were cryoprotected 
in 30% sucrose/PB at 4°C until sunk. The brains were then frozen in OCT media and a 
Leica CM1950 cryostat used to cut 35 µm sections. Free-floating IHC was performed 
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with three PB washes between each step. Endogenous peroxidase activity was removed 
with H2O2 (3%) and methanol (10%) for 30min followed by blocking and 
permeabilization with 0.5% bovine serum albumin/0.2% triton X100/PB solution for  1h. 
To label DA neurons a primary antibody against tyrosine hydroxylase (EMD Millipore; 
AB152) (1:2000 dilution) was used overnight at 4°C. A secondary antibody conjugated to 
biotin (Jackson Immuno Research) (1:500 dilution) was then applied for 1h at room 
temperature followed by ABC staining (Vector Labs) (A and B solutions at 1:100 
dilutions) for 1h. DA neurons were visualized using 3,3' diaminobenzidine (DAB) 
(Sigma Aldrich) substrate addition at 1mg/mL (pH 7.2) and allowed to develop for 4 min. 
The reaction was stopped in ddH2O, sections placed on slides, dried, and coverslips 
mounted using Vectamount. 
All DA neuron somas in the SN for all SN-containing sections in the right 
hemisphere (average of 38.6 sections per hemisphere) were counted using bright field 
microscopy. The left hemisphere was punctured with a 30-gauge needle at the time of 
cryosectioning to identify hemispheres. To correct for bisected DA neuron somas 
appearing in adjacent sections, the Abercrombie factor was determined and applied to 
counts [19]. 
Data is presented as mean ± SEM for groups. Statistical significance (p < 0.05) 
between groups was determined using multiple-way ANOVA followed by a post hoc 
Tukey’s test using GraphPad Prism 6 software.  
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Results 
 
Figure A1.  Genetic model to assess adult DA neurogenesis.  
Tamoxifen (Tam) treatment activates CRE activity in nestin or Sox2-expressing cells 
resulting in Th gene silencing. 
 
A genetic approach was developed to remove the DA neuron marker tyrosine 
hydroxylase (TH) from precursor cells in adult mice (Fig. A1). Consequently, if DA 
neurons were replenished in adult mice, there should be a gradual loss of TH positive 
neurons in the SN over time following removal of the Th gene from precursor cells. 
Tamoxifen-inducible Th excision was chosen for this drug’s ability to readily cross the 
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blood-brain barrier and good tolerability. To target NPCs for Th excision, nestin and Sox2 
promoters were selected to drive the expression of a tamoxifen-inducible CRE 
recombinase (CREERT2) in SCs and/or NPCs. Nestin and Sox2 are two of the most well-
described neural progenitor markers and are not expressed in mature neurons making 
them good initial candidates to target DA neuron precursors. Both nestin-CREERT2 [17] 
and Sox2-CREERT2 [18] mouse lines were crossed with transgenic mice possessing the 
endogenous Th gene engineered with loxP sites flanking exon 1 [16] thereby allowing for 
the excision and silencing of Th in the presence of CRE activity. Three-month-old double 
or single (control) transgenic mice (nestinCRE-ERT2:Thlox/lox, Sox2CRE-ERT2:Thlox/lox, or 
Thlox/lox) were treated with or without tamoxifen-laden chow for six weeks (Fig. A2A). 
Six months following initiation of tamoxifen treatment brains were harvested and DA 
neurons in the SN counted. Remarkably, tamoxifen treated nestinCRE-ERT2:Thlox/lox mice 
exhibited significantly fewer TH+ neurons in the SN than controls (Fig. A2B, Fig AS1). 
In addition, no reduction in TH+ cells was observed in the SN of untreated nestinCRE-
ERT2:Thlox/lox mice or tamoxifen-treated Sox2CRE-ERT2:Thlox/lox or Thlox/lox mice indicating 
that the loss in TH signal was due to Th gene excision and not the result of  non-specific 
downregulation of Th expression by tamoxifen or the presence of the CRE transgene. 
Therefore, this result indicates that a nestin-positive population of precursors replenishes 
adult DA neurons in mice. However, it was surprising to find that Sox2CRE-ERT2:Thlox/lox 
mice showed no TH+ cell loss given that Sox2 has been widely reported to be a 
ubiquitous neural SC marker [20,21].  
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Figure A2.  Adult DA neurogenesis by Nestin positive NPCs.  
Six-week treatment with tamoxifen (Tam) citrate chow (400mg/kg chow) was used to 
activate CREERT2 activity in 3-month-old transgenic mice (A). NestinCRE-
ERT2:Thlox/lox mice showed decreased DA neurons in the SN following Tam treatment 
(B). DA neurons in the SN were visualized by IHC (DAB). All sections containing SN 
from the right hemisphere were counted and neuron totals were corrected using the 
Abercrombie factor. Multiple-way ANOVA was performed followed by posthoc Tukey’s 
test (6 mice per group; error bars = SEM; * = p<0.05; ns = not significant). 
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Discussion 
This study provides compelling evidence for DA neurogenesis in the SN of adult 
mice by utilizing a novel cell lineage tracing model. Discovery of a nestin+ pool of DA 
progenitor cells will empower future studies to focus on the process of adult neurogenesis 
for DA neurons as well as enable locating these cells within the mammalian brain. 
Interestingly, this study found that Sox2 was not expressed in progenitors that gave rise 
to DA neurons in the adult SN. Sox2 expression is largely restricted to neural SCs, being 
turned down following cell cycle exit [22]. Additionally, Sox2 expression is closely 
linked to SC function, being one of four transcription factors (Oct3/4, Sox2, c-Myc, and 
Klf4) whose overexpression in concert can induce adult somatic cells to become embryo-
like SCs [23]. Nestin is an intermediate filament protein expressed by SCs and NPCs in 
vivo and in vitro and may persist for a longer period of time than Sox2 expression 
(reviewed in [24]). Thus, targeting nestin-expressing cells will affect SOX2+ SCs in 
addition to a more differentiated progenitor population. Taken together, this may suggest 
that SOX2- cells giving rise to DA neurons in the adult SN exhibit greater differentiation 
and are not renewed by SCs. The implication would be that there is a limited supply of 
DA neuron progenitors available for adult neurogenesis. Therefore, depletion of this 
progenitor pool by normal turnover or by deleterious factors would result in an eventual 
loss of mature DA neurons. Another possibility is that SCs are not needed due to 
transdifferentiation of progenitors from another cell type. Investigation of additional 
neural SC and NPC markers by cell lineage tracing in vivo might address this. 
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The cause of DA neuron loss in PD has remained a mystery despite several 
decades of intense investigation. Over this time, considerable effort has been placed in 
identifying factors that induce death of mature DA neurons in vitro and in vivo. However, 
if DA neurogenesis is a natural ongoing homeostatic mechanism in the brain as evidence 
presented here suggests, inhibition of this process could be responsible, at least in part, 
for the progressive loss of DA neurons observed in PD. Reports of heightened sensitivity 
for SC and NPC populations in the adult brain to enhanced inflammatory response and 
other toxic stimuli support this notion [25-27]. Interestingly, the rate for DA neuron loss 
in the SN using a purely inflammatory model of PD reported by two groups mirrors TH+ 
cell loss by nestin-mediated Th excision shown in Fig. 2B. Extrapolating for single brain 
hemispheres, data presented by Frank-Cannon et al. [28] and Morrison et al. [29] indicate 
an approximate rate of 14.3 and 12.3 DA neuron loss/day, respectively. If the total TH+ 
cell loss in the SN observed in Fig. 2B is divided by the tamoxifen treatment duration of 
six weeks, a rate of 13.9 ± 1.2 is yielded. This is an intriguing correlation that would also 
suggest that the enhanced inflammatory model might mediate neurodegeneration by 
impeding adult neurogenesis of DA neurons. Future studies are warranted to further 
substantiate this association. 
Findings from this study may direct stem cell replacement therapy for PD. 
Growth of stem cell research in the late 1980’s generated great interest for use of this 
technology as a potential PD treatment. However, clinical trials using fetal stem cells to 
replace lost DA neurons have yielded promising but variable results [30,31]. The 
variability was believed to result from inconsistent source stem cells. Thorough 
characterization of neural stem cells in vivo may allow for the development of 
76 
 
 
appropriate and consistent cell types for therapy. Therefore, identification and 
characterization of the newly discovered nestin+/Sox2- DA neuron precursor population 
will provide a foundation for these investigations.  
In conclusion, this study reveals the existence of a nestin+/SOX2- DA progenitor 
pool that replenishes mature DA neurons in the adult mouse SN. This finding has broad 
implications for brain biology and PD pathology and serves as a basis for future 
investigation of these important cells. 
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Figure AS1.  IHC detection of TH+ cells in the SN.  
Transgenic mice were sacrificed six months following treatment with or without 
tamoxifen (Tam)-laden chow. IHC (DAB) was then performed to quantify DA neurons in 
the SN using a TH antibody. Representative images from similar levels of the SN are 
shown. Note that differences in TH+ cell density are not readily apparent from 
comparison of single sections and require compiling DA neuron counts across all sections 
of each mouse. 
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Nigral Dopaminergic Neuron Replenishment in Adult Mice Through Ve-Cadherin-
Expressing Neural Progenitor Cells 
Citation: Rahman, A. A., Lai, N. K., Albright, J. E., Urquhart, P. E., Webb, A. R., & 
Morrison, B. E. (2017). Nigral dopaminergic neuron replenishment in adult mice through 
VE-cadherin-expressing neural progenitor cells. Neural Regeneration Research, 12(11), 
1865–1869. http://doi.org/10.4103/1673-5374.219050 
Abstract 
The function of dopaminergic neurons in the substantia nigra is of central 
importance to the coordination of movement by the brain’s basal ganglia circuitry. This is 
evidenced by the loss of these neurons, resulting in the cardinal motor deficits associated 
with Parkinson’s disease. In order to fully understand the physiology of these key 
neurons and to craft potential therapies for their loss, it essential to determine if and how 
dopaminergic neurons are replenished in the adult brain. Recent work has presented 
evidence for adult neurogenesis of these neurons by Nestin+/Sox2- neural progenitor 
cells. We sought to further validate this finding and explore a potential atypical origin for 
these progenitor cells. Since neural progenitor cells have a proximal association with the 
vasculature of the brain and the subsets of endothelial cells are Nestin+, we hypothesized 
that dopaminergic neural progenitor cells might share a common cell lineage. Therefore, 
we employed a VE-cadherin promoter-driven CREERT2:THlox/lox transgenic mouse line to 
ablate the tyrosine hydroxylase gene function from endothelial cells in adult animals. 
After six months, but not three months, following the genetic blockade of tyrosine 
hydroxylase expression in VE-cadherin+ cells, we observed a significant reduction in 
tyrosine hydroxylase+ neurons in the substantia nigra. The results from this genetic 
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lineage tracing study suggest that dopaminergic neurons are replenished in adult mice by 
a VE-cadherin+ progenitor cell population potentially arising from an endothelial cell 
lineage.  
Introduction 
The existence of adult neurogenesis for dopaminergic (DA) neurons is 
controversial. However, a major limitation of previous studies is their reliance upon 
nucleotide analog, such as bromodeoxyuridine (BrdU), incorporation to identify 
replicating neurons (Kay and Blum, 2000; Zhao et al., 2003; Frielingsdorf et al., 2004; 
Aponso et al., 2008). This approach presumes that DA neurons in adult animals are 
generated in a replication-dependent manner from neural progenitor cells (NPCs). Recent 
studies have demonstrated in multiple animal systems, including mice, that quiescent, 
non-replicative neurogenesis occurs for some neural populations within the adult brain 
(Nishimura et al., 2011; Barbosa et al., 2015; Fuentealba et al., 2015). Additionally, 
previous studies that have focused on DA adult neurogenesis employed relatively short 
labeling and post-labeling periods, thereby decreasing the ability to detect the slow 
regeneration rates (Zhao et al., 2003; Frielingsdorf et al., 2004; Arias-Carrión et al., 
2009). To avoid these potential pitfalls, we have established a transgenic mouse system 
that utilizes genetic cell lineage tracing observed over a six-month period.  
Neurons are believed to arise from ectodermal tissue during embryonic 
development, while endothelial cells likely arise from the mesoderm. However, a strong 
connection exists among vascular physiology, NPCs, and Parkinson’s disease (PD). 
NPCs in the adult brain have been reported to reside and differentiate in close association 
with capillaries, suggesting an intimate relationship with endothelial cells (Siegenthaler 
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and Pleasure, 2010). One unexplored possibility, supported by mounting evidence, is that 
specialized endothelial cells give rise to NPCs. For example, a number of factors 
associated with endothelial physiology (e.g., VEGF and endothelin) have robustly 
influenced outcomes in pre-clinical models of neurodegenerative disease (Wang et al., 
2007; Kirby et al., 2015). Remarkably, similar to DA neurons, subsets of endothelial cells 
have been demonstrated to produce and respond to dopamine (Basu et al., 2001; 
Sorriento et al., 2012). In addition, when co-cultured with endothelial cells, it has been 
reported that mouse NPCs differentiate into endothelial cells (~6% rate) capable of 
forming capillary networks, which blurs the lines between these cell types (Wurmser et 
al., 2004). 
NPCs express a number of endothelial cell markers and share common niches 
within the brain. For instance, Pramel7 was recently identified as a marker and mediator 
for a pre-implantation embryonic stem cell pluripotency ground state that has limited 
replicative self-renewal capacity (Graf et al., 2017). In situ RNA hybridization data on 
adult mouse brains available from the Allen Institute for Brain Science indicates that 
Pramel7 is expressed in the meninges, most likely in the endothelial cells (Lein et al., 
2007). Moreover, the greatest concentration of positive signal arises from the meninges 
immediately ventral to the substantia nigra. This is particularly interesting given that 
Bifari et al. recently reported that quiescent NPCs generated during embryogenesis 
migrate from the meninges to differentiate into cortical neurons without replication in 
adult mice (Bifari et al., 2016). Previous work has also shown that DA neurons in the 
substantia nigra (SN) express IL-13RA1, a histological marker for endothelial cells 
(Morrison et al., 2012). Additionally, the discovery of a Nestin+/Sox2- DA NPC 
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population in adult mice reported by Albright and colleagues may indicate an atypical 
origin for these cells since Sox2 is broadly reported as a canonical marker for NPCs 
(Albright et al., 2016). Nestin+/Sox2- cells (NeuN-; non-neural) were also described by 
Hendrickson et al. and reside in a satellite position directly neighboring mature neurons 
in the adult rat brain. This suggests that these cells may represent previously 
uncharacterized NPCs (Hendrickson et al., 2011). In addition, Nestin+ endothelial cells 
are found throughout the body (Suzuki et al., 2010). Whether there is a connection 
between Nestin+/Sox2- DA NPCs and Nestin+ endothelial cells, Nestin+ endothelial 
precursor cells, or Nestin+ mesenchymal stem cells (Pacini and Petrini, 2014) that are 
known to regulate endothelial progenitor cell differentiation and which might directly 
transdifferentiate into endothelial cells (Xie et al., 2015), could be fundamental toward 
understanding DA neurogenesis. We therefore seek to determine if adult DA NPCs are 
derived from an endothelial cell lineage. 
Materials and Methods 
Experimental Animals 
Procedures and husbandry for study animals were performed under Boise State 
University and Boise Veterans Affairs Medical Center Institutional Animal Care and Use 
Committee guidelines and in accordance with the Guide for the Care and Use of 
Laboratory Animals (National Research Council (US) Committee for the Update of the 
Guide for the Care and Use of Laboratory Animals, 2011). The THlox mouse line (Jackson 
et al., 2012) used in this study was a kind gift from Dr. Martin Darvas and Dr. Richard 
Palmiterat (The University of Washington). The VE-cadherin-CREERT2 mice were 
generously provided by Dr. Luisa Iruela-Arispe (The University of California, Los 
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Angeles). During the course of this study, mice were provided food ad libitum and 
housed with 12-hour day-night cycles. Tamoxifen treatment was administered to three-
month-old mice via standard rodent chow infused with 400 mg/kg tamoxifen citrate 
(Envigo; TD.130860), which was provided as the lone food source for a duration of six 
weeks. Following treatment, mice were returned to a standard chow diet. 
Tissue processing and immunohistochemistry 
Mice were anesthetized by isoflurane inhalation and transcardially perfused with a 
50 mL phosphate buffer (PB; pH 7.2) containing heparin sodium salt (20 units/mL) 
followed by 50 mL of a 4% paraformaldehyde (PFA) in PB solution. Mouse brains were 
collected and placed in 4% PFA/PB overnight at 4°C. The following day, the brains were 
placed in 30% sucrose/PB at 4°C until they sunk (~72 hours). Tissue was then rapidly 
frozen in OCT and stored at -80°C until immunohistochemistry (IHC) was performed.  
For IHC, OCT-embedded brains were equilibrated to a cryostat (Leica CM1950) 
at -20°C overnight. Sections were then cut at a thickness of 35 µm, placed into 12 well 
plates containing PB, and processed by free-floating IHC. Endogenous HRP activity was 
quenched with a 3% H2O2/10% methanol/PB solution incubated for 15 min at room 
temperature. Sections were then blocked and permeabilized with 0.5% BSA/0.25% 
Triton X100/PB. A TH antibody (Millipore; AB152) was used at 1:2,000 (in 0.5% 
BSA/PB), 4°C overnight. A biotinylated secondary antibody (Jackson Immuno Research; 
BA-1000) solution (1:500) was then added and incubated at room temperature for 1 h. 
Next, streptavidin-HRP was added according to manufacturer instructions (Vector Labs; 
PK-6200). Wash steps were performed using PB. TH labeling was visualized using 50 
mg/mL 3,3'-Diaminobenzidine tetrahydrochloride hydrate (DAB; VWR cat # AAJ62216-
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09) in PB. Sections were dried overnight, placed on slides, and then coverslips were 
mounted with Vectamount (Vector Labs; H-5000).  
Quantification of DA neurons in the SN 
DAB-labeled DA neurons were visualized with bright-field microscopy. For 
counting purposes, the left hemisphere was marked by piercing with a 20-gauge needle 
prior to sectioning the SN. Each tissue section containing SN from the right brain 
hemisphere was quantified following IHC. The SN was represented in an average of 38.9 
sections/hemisphere across all samples. DA neuron counts included the substantia nigra 
pars compacta and excluded TH+ neurons located in the adjoining ventral tegmental area. 
Isolation of endothelial cells and assessment of TH excision 
Primary mouse endothelial cells were obtained by magnetic-activated cell sorting 
(MACS) as previously described (Shi et al., 1999). Briefly, 6-month-old mice were 
sacrificed, one liver lobe harvested, and placed in DMEM on ice. Livers were then 
minced using sterile razor blades. Each diced liver sample was then transferred to a tube 
containing 100mg of collagenase Type I (Rockland Immunochemical; MB-118-0100) in 
25 mL of HBSS (+Calcium, +Magnesium, +1%BSA). Tubes were incubated with 
occasional mixing in a 37°C water bath for 60 minutes. Samples were then filtered 
through a 70µm sterile cell strainer and centrifuged at 300Xg for 5 min at 4°C. 
Supernatants were discarded and pellets washed once with 0.1% BSA/PBS and 
centrifuged at 300 Xg for 5 min at 4°C. Supernatants were aspirated and pellets 
resuspended in 0.5% BSA/PBS with 2mM EDTA. MACS was performed according to 
the manufacturers (MiltenyiBiotec) protocol using positive selection with CD31 
microbeads and MS columns. Following endothelial cell isolation, DNA was extracted 
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using a mouse tissue DNA extraction kit (Biopioneer; MAQ-1). PCR was performed 
using the following primers: TAGGGAGATGCCAAAGGCTA; 
CAGGACCCAACAGAAGCATT. Thermocycling was done using the following 
parameters: annealing temperature = 62C, 30 seconds; extension time = 30 seconds; 
cycles = 35.PCR products were labeled with SYBR safe and resolved on a 1.5% agarose 
gel. 
Statistical analysis 
DA neuron counts were analyzed for significance (p < 0.05) among groups using 
a multiple-way ANOVA in conjunction with a post hoc Tukey’s test using Graphpad 
Prism 6 software. Means are shown and the standard error of the mean is represented by 
error bars.  
Results 
DA NPCs express VE-cadherin 
To test whether DA neurons arise from an endothelial cell lineage in adult 
animals, we generated the transgenic mouse shown in Figure B1 where, in effect, the TH 
gene is being utilized as a genetic cell lineage tracing marker. 
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Figure B1.  Inducible transgenic mouse model for adult DA neurogenesis 
assessment. 
Three-month-old mice expressing CRE-ERT2 under the control of a VE-cadherin 
promoter were given tamoxifen (Tam)-laden chow, resulting in excision and silencing of 
the loxP-containing TH gene (homozygous) in VE-cadherin+ cells.  
 
A Vascular Endothelial Cadherin promoter was used to drive expression of a 
tamoxifen-activatable CRE recombinase (VE-cadherin CREERT2) in endothelial cells 
(Monvoisin et al., 2006). Upon activation of CRE activity by tamoxifen treatment in adult 
mice (three months of age), the tyrosine hydroxylase (TH)gene was silenced by excision 
in VE-cadherin positive cells. Six months after initiation of a six-week tamoxifen 
treatment, the mice were assessed for loss of nigral DA (TH+) neurons (Figure B2A). 
Interestingly, VE-cadherinCRE-ERT2 mice receiving tamoxifen displayed a reduction in DA 
neurons within the SN (Figure B2C). To verify whether this loss resulted from TH 
excision in DA progenitors or from existing mature DA neurons, we assessed DA 
neurons in a cohort of VE-cadherin promoter-driven CREERT2:THlox/lox mice three months 
after tamoxifen administration (Figure B2B). We observed no loss in nigral DA neurons 
in this group, indicating that TH excision occurred in cells other than mature DA neurons. 
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In addition, we confirmed successful TH excision from endothelial cells isolated from 
tamoxifen treated VE-cadherin promoter-driven CREERT2:THlox/lox mice(Figure 3). 
 
Figure B2.  Adult nigral DA neurogenesis by VE-cadherin+ progenitor cells. 
 
Tamoxifen (Tam) citrate-laden chow (400mg/kg food pellet) was fed ad libitum to three-
month-old transgenic mice (A). Brains were harvested, IHC performed for TH 
immunoreactivity, and DA neurons quantified at 13 and 26 weeks following Tam 
administration. No difference was observed among groups at three months following 
Tam treatment (B). However, at 6 months post-treatment, VE-cadherinCRE-ERT2:THlox/lox 
mice showed significantly reduced DA neurons in the SN compared with control groups 
(C). Every tissue section in the right hemisphere containing SN was counted. Statistical 
analysis was performed using a multiple-way ANOVA in conjunction with a post hoc 
Tukey’s test (group size = 6 mice; error bars = SEM; * = p<0.05 compared across all 
other groups). Nigral DA neurons were observed by IHC using a TH antibody (DAB). 
Representative images are shown (scale bar = 500 µm) (D). 
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Figure B3.  Endothelial TH excision from VE-cadherincreERT2: THlox/ox transgenic 
mouse line treated with Tamoxifen.  
 
Endothelial cells were isolated by MACS from livers harvested from untreated or TAM 
treated (400 mg/kg, 6 weeks chow) mice. DNA was then extracted and PCR performed to 
verify excision of TH in endothelial cells.  
 
Discussion 
Determining whether DA neurons undergo adult neurogenesis is of central 
importance to understanding fundamental brain physiology as well as developing 
potential therapies to combat their loss. Our current study has presented evidence in favor 
of dopaminergic neuron regeneration in adult mice through VE-cadherin-expressing 
NPCs. This finding builds upon previous work demonstrating that Nestin+/Sox2- NPCs 
in the adult mouse brain regenerate nigral DA neurons in a slow, progressive manner 
(Albright et al., 2016). These results are also consistent with the possibility of an 
endothelial cell-derived DA NPC population in adult mice.  
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The data presented here might also explain the mounting evidence linking DA 
neuron and endothelial physiology. In addition to the ability to produce and respond to 
dopamine, endothelial cells exhibit acute sensitivity to inflammatory response and 
oxidative stress (Pober and Sessa, 2007). Interestingly, oxidative stress has been shown to 
cause mesenchymal transdifferentiation of endothelial cells in vivo, providing further 
support for the plasticity of endothelial cells (Montorfano et al., 2014). If DA neurons 
share a close lineage with endothelial cells, our findings offer an explanation for the 
unique sensitivity of DA neurons toward oxidative and inflammatory response-based 
systemic insults. For example, peripheral administration of the potent oxidizing agent 
paraquat has been reported to cause the specific loss of nigrostriatal DA neurons 
(McCormack et al., 2002). In addition, systemic (intraperitoneal) administration of 
bacterial lipopolysaccharide twice weekly for six months results in chronic inflammatory 
response and in a selective, slow, and progressive loss of DA neurons in the SN (Qin et 
al., 2007; Frank-Cannon et al., 2008). Furthermore, the neurotoxic effect of MPTP on DA 
neurons can be completely halted with anti-inflammatory therapy (Aubin et al., 1998; 
Nomura et al., 2011). Similarly, NSAID use, particularly ibuprofen, has been correlated 
with a reduced incidence for PD suggesting the presence of an inflammatory instigator in 
human disease that targets these neurons (Chen et al., 2003; Gao et al., 2011). Therefore, 
a growing body of data indicates that DA neurons experience heightened sensitivity, 
compared with other neural populations, to insults that could, in part, be explained by 
physiology shared with endothelial cells.  
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Recent work by multiple groups in diverse systems has revealed the existence of 
replication-independent adult neurogenesis (Nishimura et al., 2011; Barbosa et al., 2015; 
Fuentealba et al., 2015; Bifari et al., 2016). These studies have shown that quiescent 
NPCs, produced and expanded during embryogenesis, directly differentiate into neurons 
as needed in the adult animal. If a similar mechanism is responsible for the generation of 
DA neurons in adults, it would provide an explanation for an inability to detect DA 
neurogenesis using assays that rely upon nucleotide analog incorporation (e.g., Brd-U) 
(Frielingsdorf et al., 2004). Additionally, previous studies employing a nucleotide 
labeling strategy have utilized a relatively short post-labeling period before brain 
harvesting, ranging from 8 hours to 6 weeks (Kay and Blum, 2000; Zhao et al., 2003; 
Frielingsdorf et al., 2004; Aponso et al., 2008). This approach could dramatically limit 
the ability to detect DA neurogenesis if, as our results suggest, this process occurs at a 
very slow rate and is, using our method, undetectable at three months post-labeling. If a 
replicative population of DA NPCs exists, then it will be essential to allow enough time 
for differentiation into a TH+ neuron to occur before assessment. Therefore, further 
investigations using alternative strategies, like the one demonstrated here, are warranted 
to identify the precise source of DA NPCs and characterize this regenerative process so 
that it can be harnessed for therapeutic benefit. 
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